CD13 is a critical regulator of cell-cell fusion in osteoclastogenesis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 05 2021
Historique:
received: 17 03 2021
accepted: 07 05 2021
entrez: 25 5 2021
pubmed: 26 5 2021
medline: 9 11 2021
Statut: epublish

Résumé

The transmembrane aminopeptidase CD13 is highly expressed in cells of the myeloid lineage, regulates dynamin-dependent receptor endocytosis and recycling and is a necessary component of actin cytoskeletal organization. Here, we show that CD13-deficient mice present a low bone density phenotype with increased numbers of osteoclasts per bone surface, but display a normal distribution of osteoclast progenitor populations in the bone marrow and periphery. In addition, the bone formation and mineral apposition rates are similar between genotypes, indicating a defect in osteoclast-specific function in vivo. Lack of CD13 led to exaggerated in vitro osteoclastogenesis as indicated by significantly enhanced fusion of bone marrow-derived multinucleated osteoclasts in the presence of M-CSF and RANKL, resulting in abnormally large cells containing remarkably high numbers of nuclei. Mechanistically, while expression levels of the fusion-regulatory proteins dynamin and DC-STAMP1 must be downregulated for fusion to proceed, these are aberrantly sustained at high levels even in CD13-deficient mature multi-nucleated osteoclasts. Further, the stability of fusion-promoting proteins is maintained in the absence of CD13, implicating CD13 in protein turnover mechanisms. Together, we conclude that CD13 may regulate cell-cell fusion by controlling the expression and localization of key fusion regulatory proteins that are critical for osteoclast fusion.

Identifiants

pubmed: 34031489
doi: 10.1038/s41598-021-90271-x
pii: 10.1038/s41598-021-90271-x
pmc: PMC8144195
doi:

Substances chimiques

CD13 Antigens EC 3.4.11.2

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

10736

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR055607
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR070813
Pays : United States
Organisme : NIH HHS
ID : AR070813
Pays : United States
Organisme : NIH HHS
ID : R01HL127449
Pays : United States

Références

J Immunol. 2015 May 1;194(9):4466-76
pubmed: 25801433
Dev Biol. 2007 Apr 1;304(1):317-25
pubmed: 17239847
J Cell Biol. 2014 Oct 13;207(1):73-89
pubmed: 25287300
Front Immunol. 2018 Mar 05;9:417
pubmed: 29556234
J Virol. 2017 Nov 30;91(24):
pubmed: 28978713
J Cell Biol. 2012 May 14;197(4):553-68
pubmed: 22584907
J Neurosci. 1998 Apr 15;18(8):2834-41
pubmed: 9526000
Blood. 2001 Feb 1;97(3):652-9
pubmed: 11157481
J Bone Miner Res. 2010 Jul;25(7):1468-86
pubmed: 20533309
Front Immunol. 2019 Jun 19;10:1408
pubmed: 31275328
BMC Med Genet. 2017 Nov 16;18(1):133
pubmed: 29145829
J Cell Physiol. 2010 Apr;223(1):76-83
pubmed: 20039274
J Bone Miner Res. 2012 Jan;27(1):79-92
pubmed: 21987375
J Cell Biol. 2008 Mar 10;180(5):1005-19
pubmed: 18332221
J Immunol. 2012 Jun 1;188(11):5489-99
pubmed: 22544935
J Immunol. 2015 Mar 15;194(6):2878-87
pubmed: 25694609
J Immunol. 2020 Feb 15;204(4):868-878
pubmed: 31915261
Mol Biol Cell. 2019 Aug 1;30(17):2254-2267
pubmed: 31242090
Mol Cells. 2004 Jun 30;17(3):438-45
pubmed: 15232218
Bone. 2015 Apr;73:181-9
pubmed: 25527420
Biochem Biophys Res Commun. 2015 Dec 25;468(4):611-6
pubmed: 26546825
Clin Perinatol. 2015 Jun;42(2):301-19, viii
pubmed: 26042906
Sci Signal. 2019 Apr 30;12(579):
pubmed: 31040262
Sci Rep. 2019 Jan 31;9(1):1052
pubmed: 30705363
Histol Histopathol. 2001 Apr;16(2):645-53
pubmed: 11332720
J Immunol. 2013 Oct 1;191(7):3905-12
pubmed: 23997214
J Cell Sci. 2018 Jun 5;131(11):
pubmed: 29871956
J Clin Invest. 2005 Feb;115(2):200-8
pubmed: 15690073
J Bone Miner Res. 2013 May;28(5):1203-13
pubmed: 23165930
Int J Cancer. 1993 Apr 22;54(1):137-43
pubmed: 8097496
Science. 2006 Jan 6;311(5757):83-7
pubmed: 16322423
J Bone Miner Metab. 2006;24(5):355-8
pubmed: 16937266
Nat Rev Mol Cell Biol. 2005 Jul;6(7):567-75
pubmed: 15957005
J Cell Biochem. 2013 Aug;114(8):1772-8
pubmed: 23444125
J Cell Biol. 2003 Jun 9;161(5):945-56
pubmed: 12796480
Science. 2000 Sep 1;289(5484):1504-8
pubmed: 10968780
Mol Endocrinol. 2008 Jan;22(1):176-85
pubmed: 17885208
PLoS One. 2015 Oct 22;10(10):e0141019
pubmed: 26492161
J Bone Miner Res. 2006 Jan;21(1):67-77
pubmed: 16355275
J Leukoc Biol. 2008 Aug;84(2):448-59
pubmed: 18495788
J Clin Invest. 1989 Apr;83(4):1299-307
pubmed: 2564851
Genet Mol Res. 2014 Jul 02;13(3):4776-87
pubmed: 25062413
Mol Cell Endocrinol. 2016 Sep 5;432:3-13
pubmed: 26747728
J Leukoc Biol. 2010 Aug;88(2):347-59
pubmed: 20430777
Int J Mol Sci. 2020 Aug 08;21(16):
pubmed: 32784443
J Exp Med. 1999 Dec 20;190(12):1741-54
pubmed: 10601350
Nat Rev Immunol. 2019 Oct;19(10):626-642
pubmed: 31186549
J Virol. 2004 Aug;78(16):8701-8
pubmed: 15280478
Blood. 2007 Jul 1;110(1):142-50
pubmed: 17363739
J Bone Miner Res. 2012 Jun;27(6):1289-97
pubmed: 22337159
J Exp Med. 2005 Aug 1;202(3):345-51
pubmed: 16061724
Front Physiol. 2014 Jan 09;4:402
pubmed: 24409152

Auteurs

Mallika Ghosh (M)

Center for Vascular Biology, University of Connecticut Medical School, Farmington, CT, 06030, USA. mghosh@uchc.edu.

Tomislav Kelava (T)

Center for Regenerative Medicine and Skeletal Development, University of Connecticut Dental School, Farmington, CT, 06030, USA.

Ivana Vrhovac Madunic (IV)

Center for Regenerative Medicine and Skeletal Development, University of Connecticut Dental School, Farmington, CT, 06030, USA.

Ivo Kalajzic (I)

Center for Regenerative Medicine and Skeletal Development, University of Connecticut Dental School, Farmington, CT, 06030, USA.

Linda H Shapiro (LH)

Center for Vascular Biology, University of Connecticut Medical School, Farmington, CT, 06030, USA. lshapiro@uchc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH